Results 251 to 260 of about 80,519 (274)

Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis. [PDF]

open access: yesCNS Neurosci Ther
Wang Y   +16 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Myasthenia Gravis

Seminars in Neurology, 1990
The treatment of patients with myasthenia gravis should be individualized according to the extent (ocular versus generalized) and severity (mild to severe) of disease, the presence or absence of concomitant disease (including but not limited to other autoimmune diseases and thymoma), and, to a lesser degree, the age of the patient. Thymectomy should be
D M, Linton, D, Philcox
openaire   +5 more sources

Myasthenia Gravis

Journal of Gerontological Nursing, 2013
Myasthenia gravis (MG) is a rare autoimmune disease with dysfunction of the postsynaptic transmission at the motor endplate. The early fatigue of muscle strength that varies depending on the time of day is a typical sign of MG. It is unclear, if intensive muscle training can induce early fatigue of muscle strength and lead to an exacerbation of ...
Konstantinos Lazaridis, Socrates Tzartos
  +7 more sources

Myasthenia gravis

The Indian Journal of Pediatrics, 1989
Twelve children with myasthenic symptoms were seen over a period of 6 years. The age of onset of symptoms ranged from 6 months to 9 years. On followup for a mean period of 4.25 years, (longest followup was 9 years) five children went into complete remission of symptoms after treatment with prostigmine; three children responded to prostigmine and ...
openaire   +5 more sources

Myasthenia Gravis

Seminars in Neurology, 2015
Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies directed against the postsynaptic muscle membrane. The clinical hallmark of the disease is fluctuating and fatigable weakness that affects the ocular muscles (resulting in diplopia and ptosis), the bulbar muscles (causing dysphagia, dysarthria, and dyspnea), and extremity ...
Kelly G, Gwathmey, Ted M, Burns
openaire   +2 more sources

Myasthenia Gravis

Veterinary Clinics of North America: Small Animal Practice, 1979
Myasthenia gravis is characterized by muscle weakness, which is alleviated by rest and by anticholinesterase drugs. There are two forms of the disease in the dog, acquired and congenital. The acquired form occurs either in young adults, or in older animals that have developed mediastinal tumors. Clinically, there is weakness of the muscles of the limbs,
openaire   +3 more sources

The Epidemiology of Myasthenia Gravis

Seminars in Neurology, 1994
Abstract: Population‐based studies of the epidemiology of myasthenia gravis (MG) have been conducted for over 50 years. Over that time, there has been a clear trend towards an increase in the reported prevalence of the disease. In recent years, there has also been an interest in determining a reasonably accurate estimate of the number of MG patients ...
openaire   +6 more sources

Myasthenia Gravis

Current Treatment Options in Neurology, 2010
Treatment of patients with acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the individual's needs according to disease severity (mild to severe), extent (ocular or generalized), comorbidities (including other autoimmune diseases, infections, thymoma, and pregnancy), age, iatrogenic factors (
Agnes, Jani-Acsadi, Robert P, Lisak
openaire   +2 more sources

Myasthenia gravis

Disease-a-Month, 1997
Adult-onset myasthenia gravis is an acquired autoimmune disorder of neuromuscular transmission in which acetylcholine receptor antibodies attack the postsynaptic membrane of the neuromuscular junction. Although the cause of this disease is unknown, the role of immune responses in its pathogenesis is well established.
openaire   +2 more sources

Myasthenia gravis

BMJ, 2012
Jennifer, Spillane   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy